MediWound to Host Third Quarter 2015 Financial Results Conference Call on October 28 at 8:30 a.m.

YAVNE, Israel, Oct. 16, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for the three and nine months ended September 30, 2015, after the market close on Tuesday, October 27, 2015.

MediWound's management will host a conference call for the investment community beginning at 8:30 a.m. ET on Wednesday, October 28, 2015, to discuss the financial results and to answer questions.

Shareholders and other interested parties may participate in the conference call by dialing (877) 280-2296 (US) or (809) 212-923 (Israel) and entering passcode 9428013. The call will also be broadcast live on the Internet on the Company's website at www.mediwound.com.

A replay of the call will be accessible two hours after its completion until midnight November 4, 2015 Eastern time by dialing (866) 932-5017 (US) or (800) 358-7735 (UK) and entering passcode 9428013#. The call will also be archived on the Company's website for 90 days at www.mediwound.com.

About MediWound Ltd.

MediWound is a biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, as well as chronic and other hard-to-heal wounds. MediWound's first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and has been launched in Europe and Israel. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. For more information, please visit www.mediwound.com.